S U M M A R Y
Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risks of diabetes, cardiovascular disease and also for Chronic Kidney Disease. A high body mass index is one of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a series of complex pathophysiologic changes occur that lead to the development of Chronic Kidney Disease. These include on the one hand effects mediated by the downstream consequences of obesity (such as diabetes mellitus and hypertension), but also direct effects of adipose tissue, via humoral factors such as leptin, adiponectin, resistin and visfatin). In obese individuals a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight, leading to glomerulomegaly and accompanied by deposition of adipose tissue in the glomerulus and the gradual development of focal segmental glomerulosclerosis. The incidence of obesity-related glomerulopathy has increased ten-fold in recent years. In addition to the development of Chronic Kidney Disease, obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. Interventions to stem the tide of obesity are thus extremely important for preventing the development and progression of Chronic Kidney Disease and other disorders of the kidneys. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option. Definitions of obesity are typically based on BMI. Although BMI is easy to calculate, it is a poor estimate of fat mass distribution. Alternative parameters to more accurately capture visceral fat include waist circumference (WC) and a waist hip ratio (WHR) of >102 cm and 0.9, respectively, for men and >88 cm and >0.8, respectively, for women. WHR has been shown to be superior to BMI for the correct classification of obesity in CKD.
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ASSOCIATION OF OBESITY WITH CKD AND OTHER RENAL COMPLICATIONS
Numerous studies have shown an association between measures of obesity and both the development and the progression of CKD (Table 1 ). In general, the associations between obesity and poorer renal outcomes persist even after adjustments for possible mediators of obesity's cardiovascular and metabolic effects, such as high blood pressure and diabetes mellitus, suggesting that obesity may affect kidney function through mechanisms in part unrelated to these complications (vide infra). The deleterious effect of obesity on the kidneys extends to other complications such as nephrolithiasis (Curhan et al. 1998; Scales et al. 2012 ) and kidney malignancies (Renehan et al. 2008; Bhaskaran & Douglas 2014; Arnold et al. 2015) .
MECHANISMS OF ACTION UNDERLYING THE RENAL EFFECTS OF OBESITY
The exact mechanisms whereby obesity may worsen or cause CKD remain unclear. Some of the deleterious renal consequences of obesity may be mediated by downstream comorbid conditions such as diabetes mellitus or hypertension, but there are also effects of adiposity which could impact the kidneys directly, induced by the endocrine activity of the adipose tissue via production of (among others) adiponectin (Sharma 2009 ), leptin (Wolf & Ziyadeh 2006) and resistin (Ellington et al. 2007 ) (Figure 1 ). These include the development of inflammation (Bastard et al. 2006) , oxidative stress (Furukawa et al. 2004) , abnormal lipid metabolism, (Ruan et al. 2009 ) activation of the reninangiotensin-aldosterone system (Ruster & Wolf 2013) , and increased production of insulin and insulin resistance (Reaven 1988; Oterdoom et al. 2007 ).
These various effects result in specific pathologic changes in the kidneys (Kambham et al. 2001) including ectopic lipid accumulation (de Vries et al. 2014 ) and increased deposition of renal sinus fat (Henegar et al. 2001; Foster et al. 2011a) , the development of glomerular hypertension and increased glomerular permeability caused by hyperfiltration-related glomerular filtration barrier injury (Knight et al. 2008) , and ultimately the development of glomerulomegaly (Tsuboi et al. 2012) , and focal or segmental glomerulosclerosis (Kambham et al. 2001 ) (Figure 2 ). The incidence of the so-called obesity-related glomerulopathy has increased 10-fold between 1986 and 2000 (Kambham et al. 2001) .
Obesity is associated with a number of risk factors contributing to the higher incidence and prevalence of nephrolithiasis, such as lower urine pH (Maalouf et al. 2004 ) and increased urinary oxalate (Lemann et al. 1996) , uric acid, sodium and phosphate excretion (Siener et al. 2004) . The insulin resistance characteristic of obesity may also predispose to nephrolithiasis ) through its impact on tubular Na-H exchanger (Klisic et al. 2002) and ammoniagenesis (Chobanian & Hammerman 1987) , and the promotion of an acidic milieu (Daudon et al. 2006) .
The mechanisms behind the increased risk of kidney cancers observed in obese individuals are less well characterised. Insulin resistance, chronic hyperinsulinemia and increased production of insulin-like growth factor 1 may exert stimulating effects on the growth of various types of tumor cells (Calle & Kaaks 2004) . More recently, the endocrine functions of adipose tissue (Dalamaga et al. 2012) , its effects on immunity (Lamas et al. 2002) , and the generation of an inflammatory milieu with complex effects on cancers (Grivennikov et al. 2010; Lim & Savan 2014) have emerged as additional explanations.
OBESITY IN PATIENTS WITH ADVANCED KIDNEY DISEASE: THE NEED FOR A NUANCED APPROACH
In a seemingly counterintuitive manner obesity has been consistently associated with lower mortality rates in patients with advanced CKD (Kovesdy et al. 2007; Lu et al. 2014) and ESRD (Beddhu et al. 2003; Kalantar-Zadeh et al. 2006) . It is possible that the seemingly protective effect of a high BMI is the result of the imperfection of BMI as a measure of obesity. However, there is also evidence to suggest that higher adiposity, especially subcutaneous (non-visceral) fat, may also be associated with better outcomes in ESRD patients (Kalantar-Zadeh et al. 2006) . Such benefits may be present in patients who have very low short term life expectancy, such as most ESRD patients; (Dekker et al. 2008) including benefits from better nutritional status, higher muscle mass, (Beddhu et al. 2003 ) a more stable haemodynamic status with mitigation of stress responses and heightened sympathetic and renin-angiotensin activity (Horwich et al. 2001) ; increased production of adiponectines (Stenvinkel et al. 2004) and soluble tumor necrosis factor alfa receptors (Mohamed-Ali et al. 1999; Rauchhaus et al. 2000) and sequestration of uraemic toxins by adipose tissue (Jandacek et al. 2005) .
POTENTIAL INTERVENTIONS FOR MANAGEMENT OF OBESITY
Strategies for controlling the obesity-related CKD epidemic at population level and for countering the evolution of CKD towards kidney failure in obese patients represent the most tantalizing task that today's health planners, health managers and nephrologists face. COUNTERING CKD AT POPULATION LEVEL Calls for public health interventions in the community to prevent and treat CKD at an early stage have been made by major renal associations. In the United States, Healthy People 2020, a program that sets 10-year health targets for health promotion and prevention goals, focuses both on CKD and obesity. A successful surveillance system for CKD has already been implemented in some places such as the United Kingdom (O'Donoghue & Stevens 2012), which may serve as a platform to improve the prevention of obesity-related CKD. Campaigns aiming at reducing the obesity burden are now at centre stage worldwide and are strongly recommended by the WHO and it is expected that these campaigns will reduce the incidence of obesity-related complications, including CKD.
PREVENTION OF CKD PROGRESSION IN OBESE PEOPLE WITH CKD
Obesity-related goals in obese CKD patients remain vaguely formulated, largely because of the paucity of high-level evidence intervention studies to modify obesity in CKD patients (Bolignano & Zoccali 2013) . In overweight or obese diabetic patients, a lifestyle intervention including caloric restriction and increased physical activity compared with a standard follow up reduced the risk for incident CKD by 30% (Wing et al. 2013) . In a recent meta-analysis collating experimental studies in obese CKD patients, interventions aimed at reducing body weight showed coherent reductions in blood pressure, glomerular hyperfiltration and proteinuria (Bolignano & Zoccali 2013) . A post hoc analysis of the REIN study showed that the nephron-protective effect of ACE inhibition in proteinuric CKD patients was maximal in obese CKD patients, but minimal in CKD patients with normal or low BMI (Mallamaci et al. 2011) . Bariatric surgical intervention have been suggested for selected CKD and ESRD patients (Jamal et al. 2015; Chang et al. 2016; Friedman & Wolfe 2016) .
Globally, these experimental findings provide a proof of concept for the usefulness of weight reduction and ACE inhibition interventions in the treatment of CKD in the obese. Studies showing a survival benefit of increased BMI in CKD patients, however, remain to be explained (Ahmadi et al. 2015) . These findings limit our ability to make strong recommendations about the usefulness and the safety of weight reduction among individuals with more advanced stages of CKD. Lifestyle recommendations to reduce body weight in obese people at risk for CKD and in those with early CKD appear justified, particularly recommendations for the control of diabetes and hypertension. 
CONCLUSIONS
The worldwide epidemic of obesity affects the Earth's population in many ways. Diseases of the kidneys, including CKD, nephrolithiasis and kidney cancers are among the more insidious effects of obesity, but which nonetheless have wide ranging deleterious consequences, ultimately leading to significant excess morbidity and mortality and excess costs to individuals and the entire society. Population-wide interventions to control obesity could have beneficial effects in preventing the development, or delaying the progression of CKD. It is incumbent upon the entire healthcare community to devise long-ranging strategies towards improving the understanding of the links between obesity and kidney diseases, and to determine optimal strategies to stem the tide. The 2017 World Kidney Day is an important opportunity to increase education and awareness to that end.
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